Document is current
Any future updates will be listed below
-
Authors
ter Heine, Rob https://orcid.org/0000-0003-2185-8201
van den Heuvel, Michel M.
Piet, Berber
Deenen, Maarten J.
van der Wekken, Anthonie J.
Hendriks, Lizza E. L.
Croes, Sander
van Geel, Robin M. J. M.
Jansman, Frank G. A.
Boshuizen, Rogier C.
Franssen, Eric J. F.
Smit, Arthur A. J.
Dumoulin, Daphne W.
Oude Munnink, Thijs H.
Smit, Egbert F.
Derijks, Hieronymus J.
van der Leest, Cor H.
Hendrikx, Jeroen J. M. A.
Moes, Dirk J. A. R.
de Rouw, Nikki
- License Information
-
More Information
Article History
Accepted: 15 March 2023
First Online: 21 April 2023
Declarations
:
: No external funding was used in the preparation of this article.
: Rob ter Heine has received fees or funding from Stichting Treatmeds and Amgen. Anthonie van der Wekken has received fees or funding from AstraZeneca, Boehringer Ingelheim, Pfizer Roche, Takeda, Janssen Cilag, Lilly, and Merck. Michel van den Heuvel has received fees or funding from Amgen, Astrazeneca, BMS, Janssen Pharmaceutica, Stichting Treatmeds, Merck, MSD, Novartis, Pamgene, Pfizer, Roche, Roche diagnostics, Abbvie, Astrazeneca, BMS, Lilly, MSD, Novartis, Pfizer, and Roche. Daphne Dumoulin has received funding from Roche, BMS, MSD, Astra Zeneca, Amgen, and Pfizer. Cor van der Leest has received fees or funding from BMS and MSD en Janssen. Lizza Hendriks has received fees or funding from Roche Genentech, AstraZeneca, Boehringer Ingelheim, Takeda, Merck, Pfizer, Benecke, Medtalks, VJOncology, high5oncology, BMS, Eli Lilly, Takeda, MSD, Merck, Novartis, Amgen, and Janssen. Sander Croes, Robin van Geel, Frank Jansman, Rogier Boshuizen, Egbert Smit, Arthur Smit, Thijs Oude Munnink, Hieronymus Derijks, Jeroen Hendrikx, Dirk Jan Moes, and Nikki de Rouw have no conflicts of interest that are directly relevant to the content of this article.
: Not applicable.
: Not applicable.
: Not applicable.
: All model files to generate the presented data are provided in the Electronic Supplementary Material.
: Not applicable.
